ArticleBMJ open2014
Multi-institution case-control and cohort study of risk factors for the development and mortality of Clostridium difficile infections in Japan.
Article in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects.Clinical drug investigation · 2015Trial
- Incidence of hospital-acquired toxin-producing clostridioides difficile infection between the pre-pandemic (2017-2019) and pandemic (2020-2022): a retrospective cohort study.Archives of public health = Archives belges de sante publique · 2026Article
- Controversies in the Prevention and Treatment ofMicroorganisms · 2023Review
- Mortality FollowingAntibiotics (Basel, Switzerland) · 2021Article
- Excess length of hospital stay, mortality and cost attributable toEpidemiology and infection · 2020Article
- Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing ofAntimicrobial agents and chemotherapy · 2019Article
- Predictors of Mortality Among a National Cohort of Veterans With RecurrentOpen forum infectious diseases · 2018Article
- Factors affecting development of Clostridium difficile infection in hospitalized pediatric patients in the country Georgia.BMC research notes · 2018Article
- Characteristics and Immunological Roles of Surface Layer Proteins in Clostridium difficile.Annals of laboratory medicine · 2018Review
- The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review.Infectious diseases and therapy · 2018Review
- Post-hospitalization Treatment Regimen and Readmission for C. difficile Colitis in Medicare Beneficiaries.World journal of surgery · 2018Article
- Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Observational
- Hospital-acquired Clostridium difficile infection in Mainland China: A seven-year (2009-2016) retrospective study in a large university hospital.Scientific reports · 2017Article
- Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.Internal and emergency medicine · 2016Article
- Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease.Epidemiology and infection · 2016Article
- Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.World journal of gastroenterology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine risk factors for Clostridium difficile infection (CDI) morbidity and mortality in Japan.
designMultimethod investigation including a case-control study and cohort study.
setting47 participating facilities of the National Hospital Organization (NHO).
participants1026 patients with CDI and 878 patients in the control group over the age of 18 years admitted to the subject NHO facilities from November 2010 to October 2011.
main outcome measuresIn a case-control study, we identify risk factors for CDI development. Next, in a cohort study, we identify risk factors for all-cause mortality within 30 days following CDI onset.
resultsA total of 1026 cases of CDI meeting the definitions of this investigation were identified, encompassing 878 patients at 42 of the 47 subject facilities. In the case-control study, we identified, compared with no antibiotics use, use of first-generation and second-generation cephem antibiotics (OR 1.44; 95% CI 1.10 to 1.87), use of third-generation and fourth-generation cephem antibiotics (OR 1.86; 95% CI 1.48 to 2.33) and use of carbapenem antibiotics (OR 1.87; 95% CI 1.44 to 2.42) the risk factors for CDI development. However, use of penicillin was not identified as a risk factor. In the cohort study, sufficient data for analysis was available for 924 CDI cases; 102 of them (11.0%) resulted in death within 30 days of CDI onset. Compared with no anti-CDI drug use, use of vancomycin was associated with reduced risk of mortality (OR 0.43; 95% CI 0.25 to 0.75) whereas metronidazole was not.
conclusionsThe findings mirror those of previous studies from Europe and North America, identifying the administration of broad-spectrum antibiotics as a risk factor for CDI development. The use of vancomycin is associated with a decreased risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.